11:23 EDT Prothena sinks 20% to $16.11 following exit of Chief Medical Officer
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena Leadership Transition Amid Neurodegenerative R&D Push
- Prothena names Chad Swanson, Ph.D. as Chief Development Officer
- Prothena price target lowered to $62 from $66 at Oppenheimer
- 3 Small-Cap Stocks with Big Potential, Say Analysts (8/13/24)
- Prothena price target lowered to $24 from $28 at RBC Capital